Loading of STING Agonist into Lipid Nanoparticles Boosts Dendritic Cell Activation

Area of Science:

• Immunology
• Nanotechnology
• Cancer Research

Background:

• STING pathway activation is vital for antitumor immunity.
• Inefficient intracellular delivery of STING agonists hinders therapeutic targeting.
• Lipid nanoparticles (LNPs) offer a potential solution for drug delivery.

Purpose of the Study:

• To evaluate FDA-approved LNPs for delivering a STING agonist (cG^sA^sMP) to dendritic cells (DCs).
• To assess the potential of cG^sA^sMP-loaded LNPs in activating DCs and reprogramming tumor-associated DCs for cancer immunotherapy.

Main Methods:

• Utilized FDA-approved lipid nanoparticles (LNPs) for encapsulation of cGAMP analog (cG^sA^sMP).
• Investigated LNP uptake and cargo release in DCs in vitro.
• Developed and employed an in vitro model of tumor-associated human DCs.

Main Results:

• LNPs efficiently encapsulated and delivered cG^sA^sMP to DCs, enhancing STING activation and DC maturation.
• cG^sA^sMP-loaded LNPs successfully reprogrammed tumor-associated DCs toward an active phenotype.
• The LNP formulation proved reproducible, scalable, and effective in enhancing DC activation.

Conclusions:

• Lipid nanoparticles provide a scalable and effective platform for delivering STING agonists like cG^sA^sMP.
• This approach holds significant potential for cancer immunotherapy by overcoming immune suppression.
• Targeting STING activation via LNP delivery represents a promising strategy for enhancing antitumor responses.